CD66e Recombinant Antibody for Research: Quality and Performance Insights

The CD66e recombinant antibody from Alpha Lifetech Incorporation represents a significant advancement in the field of immunology and biomedical research. This high-quality recombinant antibody is designed to specifically target the CD66e antigen, which plays a crucial role in cell adhesion and immune response. With its exceptional specificity and affinity, this antibody is ideal for various applications, including flow cytometry, immunohistochemistry, and ELISA, Researchers can depend on CD66e recombinant antibody for reliable results in studies related to cancer, autoimmune diseases, and infectious diseases. Each batch is rigorously tested for performance and consistency, ensuring optimal user experience and reproducibility in experiments. The antibody is available in multiple formats to accommodate a wide range of research needs, Enhance your research with the CD66e recombinant antibody and explore new frontiers in the understanding of cell biology and disease mechanisms. Alpha Lifetech Incorporation remains committed to providing top-tier reagents that empower scientists in their pursuit of innovation

Hot Selling Product

ADT1127-Cergutuzumab Amunaleukin Biosimilar-(CEACAM5/CEA/CD66e)-Research Biosimilar Antibody

ADT1026-Altumomab Biosimilar (CEACAM5/CD66e)-Research Biosimilar Antibody

ALP64505-Recombinant Human CD24 Protein, mFc Tag

ALP64510-Recombinant Cynomolgus Monkey SIRP alpha/CD172a Protein, His Tag

ALP64567-Recombinant Rabbit CD86 Protein, His Tag

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

Why Opt For cd66e recombinant antibody Supplies the World’s Top Brands From Concept to Delivery

In the rapidly evolving landscape of biopharmaceuticals, the demand for high-quality reagents has never been greater. This is where Alpha Lifetech Inc. stands out, particularly with our cd66e recombinant antibody. Developed by a team of seasoned scientists with deep expertise in membrane protein production, Nanobody discovery, and monoclonal development, our offerings cater to the rigorous needs of top brands worldwide. The cd66e recombinant antibody is not just a product; it's a testament to our commitment to quality and innovation. With a portfolio that includes nearly 10,000 specialized reagents, cytokines, and drug target antibodies, we ensure that our clients receive unparalleled support from the initial concept to final delivery. By choosing Alpha Lifetech, global buyers benefit from our comprehensive understanding of the market and the scientific rigor behind our products, enabling them to optimize their research and development processes effectively. Partnering with us means gaining access to cutting-edge solutions that facilitate advancements in therapeutics and diagnostics. We pride ourselves not only on the quality of our reagents but also on our dedication to customer satisfaction and timely delivery. With Alpha Lifetech Inc. as your supplier, you are equipped to push the boundaries of science and innovation in your own projects.

Why Opt For cd66e Recombinant Antibody Supplies the World’s Top Brands From Concept to Delivery

Antibody Type	Applications	Target Species	Concentration	Delivery Time
Recombinant Anti-cd66e	Western Blot, ELISA	Human	1 mg/mL	2-3 weeks
Recombinant Anti-cd66e	Immunohistochemistry	Mouse	500 µg/mL	3-4 weeks
Recombinant Anti-cd66e	Flow Cytometry	Rat	2 mg/mL	1-2 weeks
Recombinant Anti-cd66e	ELISPOT	Bovine	200 µg/mL	4-6 weeks

Annual Growth Rate of Recombinant Antibodies (2018-2023)

The chart above illustrates the annual growth rate of the recombinant antibody market from 2018 to 2023. Starting in 2018, the market experienced a modest growth rate of 10%. As researchers and developers increasingly recognized the potential of recombinant antibodies for therapeutic and diagnostic applications, the growth rate accelerated to 15% in 2019 and reached 20% in 2020. The upward trend continued robustly, with a notable increase to 30% in 2021, driven by advancements in biotechnology and rising demand in various biomedical sectors. Although the growth rate saw a slight decline to 25% in 2022, reflecting market adjustments and increased competition, the forecast for 2023 indicates a significant rebound to 35%. This resurgence is attributed to the continuous innovation in antibody engineering and the growing investment in biopharmaceutical research. Overall, the data highlights a promising outlook for the recombinant antibody market, signifying its vital role in the future of medical science and treatment methodologies.